Cord blood/bone marrow stem cell therapy-heart disease - Gamida Cell

Drug Profile

Cord blood/bone marrow stem cell therapy-heart disease - Gamida Cell

Alternative Names: CardioCure; Cord blood stem cell therapy-myocardial infarction - Gamida-Cell; EE-AC133+; GC 011

Latest Information Update: 12 Dec 2013

Price : $50

At a glance

  • Originator Gamida-Cell
  • Class
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Myocardial infarction

Most Recent Events

  • 31 Dec 2011 No development reported - Preclinical for Myocardial infarction in Israel (unspecified route)
  • 08 Jan 2007 Data presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH-2006) added to the Ischaemic Heart Disease pharmacodynamics section
  • 15 Nov 2006 Preclinical development of the cardiac regeneration product is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top